Soligenix, Inc. (SNGX) Dividend History

Company News

• Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight

  The cutaneous T-cell lymphoma market is expected to grow at a 7.1% CAGR from 2020-2034, driven by research advancements, increasing prevalence, and emerging therapies targeting this rare lymphoma.

  GlobeNewswire Inc.
• Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

  Soligenix's HyBryte™ treatment showed a 75% positive outcome in early-stage cutaneous T-cell lymphoma (CTCL) patients after 18 weeks, reinforcing its potential as a safe and fast-acting therapy for this rare cancer.

  Benzinga
• Soligenix stock rallies 400% on positive HyBryte trial results - Invezz

  Soligenix reported positive interim data from a trial of its HyBryte therapy, with three out of six enrolled patients meeting the success criteria. The company plans to enroll a total of 50 patients and is working towards a confirmatory Phase 3 study.

  Invezz
• Don’t Trade Penny Stocks Until You’ve Taken These Steps

  Here's 3 steps to take prior to trading penny stocks in 2024 The post Don’t Trade Penny Stocks Until You’ve Taken These Steps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: JAGX SPCB